Harness Therapeutics is a Cambridge, UK–based biotechnology company developing oligonucleotide-based therapies to upregulate protein expression for neurodegenerative diseases. The company leverages insights into RNA biology and post-transcriptional regulation, originally advancing an IncRNA “SINEUP” platform and subsequently broadening its oligonucleotide toolset and bespoke analytical capabilities. It focuses on neurodegeneration targets with strong biological and genetic validation and is led by CEO Jan Thirkettle. Its lead programme targets the FAN1 nuclease for Huntington’s Disease. The company intends to use the new funding to advance that programme towards the clinic. To date the company has raised a total of £17.6M, including the additional £4M reported in this round. Transine Therapeutics is a Cambridge, UK–based biotechnology company that has developed the SINEUP® platform to create a novel class of therapeutic RNAs that bind mRNA and enhance translation to upregulate target proteins. The company is pursuing programmes across Central Nervous System and Ophthalmology indications and currently reports three active programmes. Transine says it expects key in vivo data this year and aims to leverage its platform broadly across diseases with unmet needs. The team was founded by Professors Piero Carninci and Stefano Gustincich and combines expertise in RNA biology, drug discovery and platform commercialisation. Recent financing strengthens its balance sheet to accelerate platform and product development and support further partnering options. Transine Therapeutics is a private biotech developing a novel class of therapeutic RNAs—SINEUPs®—that upregulate endogenous protein expression by enhancing mRNA translation. Synthetic SINEUPs® are described as universal, specific, tunable and able to raise protein levels within a physiological range, aiming to extend the druggable proteome beyond the reach of small molecules, conventional biologics or gene therapies. The modular platform enables rapid design of SINEUPs for almost any mRNA target and supports delivery‑agnostic approaches including naked oligonucleotides, AAV vectors, or non‑viral systems. Transine plans to build a pipeline of mRNA‑targeted therapeutics initially focused on central nervous system and ophthalmology applications. The company closed an extended £9.1M seed round co‑led by Takeda Ventures and the Dementia Discovery Fund to advance its proprietary platform and pipeline. Founded in 2020 and based at the Babraham Research Campus in Cambridge, UK, Transine was founded on work by Professors Stefano Gustincich and Piero Carninci and is backed by Takeda Ventures and DDF.

Total raised

$24M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2023